Generated by AI
Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics for disorders linked to dysfunctional signaling in the transforming growth factor-beta family of proteins. Its current pipeline centers on candidates designed to address serious hematologic, pulmonary, cardiovascular, and musculoskeletal conditions, with research programs aimed at low blood cell counts, anemia, pulmonary arterial hypertension, bone-related disorders, and muscle-related diseases. The company’s work is built around protein- and pathway-based approaches that target disease mechanisms involved in red blood cell and platelet production, iron regulation, and tissue repair. Keros Therapeutics serves the biotechnology and specialty medicine markets, where it contributes to the development of precision therapies for patients with high unmet medical needs.
Website1050 Waltham Street
Lexington, MA, 02421
United States
The latest articles about KROS.
LEXINGTON, Mass., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a new $5 million share repurchase program of the Company’s
Summary of Oct 15's posts. Generated by AI.
Summary of Apr 10's posts. Generated by AI.
No summary yet.
Summary of Jun 9's posts. Generated by AI.
Investors talking about KROS also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.